Australia Bans Andrographis Paniculata In Supplements

The TGA has removed the ingredient from its registry following serious safety concerns linked to anaphylaxis.

Updated on Oct. 21, 2026 in Allergies

Bold flat-color editorial illustration of a single jagged botanical leaf, symbolizing the regulatory ban on a hazardous herbal supplement ingredient. — The Australian Therapeutic Goods Administration has officially banned Andrographis paniculata from all supplements following a reported death and anaphylaxis risks. AI Illustration. Upload story photo >

Live Poll

Do you trust current government processes to adequately identify and remove unsafe health supplement ingredients?

The Therapeutic Goods Administration has removed Andrographis paniculata from the Australian Register of Therapeutic Goods. The regulator cited the risk of anaphylaxis and one reported death as primary reasons for the ban.

Why it matters

The TGA determined that health risks associated with the ingredient cannot be managed under the listed medicine pathway. By removing it, the agency aims to prevent further severe allergic reactions among consumers.

The TGA confirmed one reported death associated with the ingredient, which is no longer classified as low-risk. New products containing it are now prohibited from being included on the Australian Register of Therapeutic Goods.

The players

Therapeutic Goods Administration

This is the Australian government agency responsible for evaluating and monitoring the safety, quality, and efficacy of medicines and medical devices.

The details

Companies were ordered to recall existing cold and flu supplements containing the ingredient to ensure market safety. Products are being removed from shelves as the regulator ceases the inclusion of new items containing this substance.

September 2026: The TGA issued a statement regarding the ingredient risk.
15 October 2026: The regulatory action reached the market.
October 2026: Deadline for companies to remove products from the market.

Health Landscape

The removal of a substance from the Australian Register of Therapeutic Goods marks a shift in how the TGA handles safety risks compared to its previous low-risk classification policies.

Consumers should check the labels of their current cold and flu supplements for this ingredient and discontinue use if found. Patients who have experienced reactions should consult their healthcare provider for guidance.

The takeaway

Consumers should always verify that their health supplements are approved by the relevant national authority. When a product is flagged for severe risks like anaphylaxis, it is essential to follow official recall notices promptly.